NCT05915377 Researching Efficient Approaches to Delirium Identification-Sustaining Effective Translation
| NCT ID | NCT05915377 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Penn State University |
| Condition | Delirium |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,050 participants |
| Start Date | 2024-04-03 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,050 participants in total. It began in 2024-04-03 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this step-wedge trial is to test the implementation of daily nurse screening for delirium in routine care and its impact on outcomes and complications in hospitalized older adults admitted to 6 general medicine/surgery units at 3 hospitals in Pennsylvania and Massachusetts. The main question\[s\] it aims to answer are: * 1\. To test the fidelity, accuracy, and durability of implementing daily nurse screening for delirium using the UB-CAM in routine care. * 2\. To evaluate the impact of UB-CAM delirium screening on patient and care partner centered outcomes assessed at one month follow-up interviews 3. To evaluate the impact of UB-CAM screening on rates of delirium complications (falls, pressure injury, aspiration) and adverse delirium management (psychoactive medication use, restraint use). Participants (patients) will be assessed for delirium on study days 1, 2 and 3 (or until hospital discharge) and will be asked basic demographics. These patients will be contacted by phone 1 month after enrollment to collect information about inpatient facility use and to administer the Delirium Burden Patient Scale. Participants (care partners) will be interviewed at the patient's discharge to complete the Alzheimer's Disease-8 scale. These care partners will be contacted by phone 1 month after enrollment to complete the Delirium Burden Caregiver Scale and to complete a Qualitative Interview which includes questions about communication and collaboration.
Eligibility Criteria
Inclusion Criteria: * General medicine (hospitalist) service * Age 70 or older * Expected hospital length of stay of 3 or more days Exclusion Criteria: * Inability to communicate adequately in English * Admitted for terminal care
Contact & Investigator
Donna M Fick, PhD
PRINCIPAL INVESTIGATOR
Penn State University
Frequently Asked Questions
Who can join the NCT05915377 clinical trial?
This trial is open to participants of all sexes, aged 70 Years or older, studying Delirium. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05915377 currently recruiting?
Yes, NCT05915377 is actively recruiting participants. Contact the research team at dmf21@psu.edu for enrollment information.
Where is the NCT05915377 trial being conducted?
This trial is being conducted at Boston, United States, State College, United States.
Who is sponsoring the NCT05915377 clinical trial?
NCT05915377 is sponsored by Penn State University. The principal investigator is Donna M Fick, PhD at Penn State University. The trial plans to enroll 1,050 participants.